Sato, Y.; Nakano, K.; Wang, X.; Fukuda, N.; Urasaki, T.; Ohmoto, A.; Hayashi, N.; Yunokawa, M.; Ono, M.; Tomomatsu, J.;
et al. Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma. Cancers 2021, 13, 6266.
https://doi.org/10.3390/cancers13246266
AMA Style
Sato Y, Nakano K, Wang X, Fukuda N, Urasaki T, Ohmoto A, Hayashi N, Yunokawa M, Ono M, Tomomatsu J,
et al. Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma. Cancers. 2021; 13(24):6266.
https://doi.org/10.3390/cancers13246266
Chicago/Turabian Style
Sato, Yasuyoshi, Kenji Nakano, Xiaofei Wang, Naoki Fukuda, Tetsuya Urasaki, Akihiro Ohmoto, Naomi Hayashi, Mayu Yunokawa, Makiko Ono, Junichi Tomomatsu,
and et al. 2021. "Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma" Cancers 13, no. 24: 6266.
https://doi.org/10.3390/cancers13246266
APA Style
Sato, Y., Nakano, K., Wang, X., Fukuda, N., Urasaki, T., Ohmoto, A., Hayashi, N., Yunokawa, M., Ono, M., Tomomatsu, J., Saito, M., Minami, Y., Hayakawa, K., Funauchi, Y., Tanizawa, T., Ae, K., Matsumoto, S., & Takahashi, S.
(2021). Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma. Cancers, 13(24), 6266.
https://doi.org/10.3390/cancers13246266
